Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis - PubMed (original) (raw)
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
H Takayanagi et al. Arthritis Rheum. 2000 Feb.
Free article
Abstract
Objective: To clarify the mechanism by which osteoclasts are formed in culture of rheumatoid synoviocytes by exploring the involvement of receptor activator of nuclear factor kappaB ligand (RANKL)/osteoclast differentiation factor (ODF).
Methods: Osteoclast formation was evaluated in cocultures of rheumatoid synovial fibroblasts and peripheral blood mononuclear cells (PBMC) in the presence of macrophage colony stimulating factor and 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) utilizing separating membrane filters. RANKL/ODF expression was examined by Northern blotting in synovial tissues from 5 rheumatoid arthritis (RA) patients and tissues from patients with giant cell tumor (GCT), osteosarcoma (OS), and osteoarthritis (OA). RANKL/ODF expression and the ability of synovial fibroblasts to support osteoclastogenesis were investigated in coculture with PBMC in the presence or absence of 1,25(OH)2D3, and soluble RANKL/ODF and osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) were measured by enzyme-linked immunosorbent assay. The effects of OPG/OCIF on the osteoclastogenesis in the primary culture of rheumatoid synoviocytes and the coculture system were determined.
Results: Synovial fibroblasts did not induce osteoclastogenesis when separately cocultured with PBMC. Northern blotting revealed that RANKL/ODF was highly expressed in all tissues from RA and GCT patients, but not from OA or OS patients. Cultured rheumatoid synovial fibroblasts efficiently induced osteoclastogenesis in the presence of 1,25(OH)2D3, which was accompanied by up-regulated expression of RANKL/ODF and decreased production of OPG/OCIF. Osteoclastogenesis from synoviocytes was dose-dependently inhibited by OPG/OCIF.
Conclusion: RANKL/ODF expressed on synovial fibroblasts is involved in rheumatoid bone destruction by inducing osteoclastogenesis and would therefore be a good therapeutic target.
Similar articles
- Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N. Kotake S, et al. Arthritis Rheum. 2001 May;44(5):1003-12. doi: 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#. Arthritis Rheum. 2001. PMID: 11352231 - Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T. Itoh K, et al. J Bone Miner Res. 2000 Sep;15(9):1766-75. doi: 10.1359/jbmr.2000.15.9.1766. J Bone Miner Res. 2000. PMID: 10976996 - Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
Kubota A, Hasegawa K, Suguro T, Koshihara Y. Kubota A, et al. J Rheumatol. 2004 Mar;31(3):426-35. J Rheumatol. 2004. PMID: 14994384 - A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Takahashi N, Udagawa N, Suda T. Takahashi N, et al. Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252. Biochem Biophys Res Commun. 1999. PMID: 10080918 Review. - [OPG, anti-rANKL antibody].
Yasuda H. Yasuda H. Nihon Rinsho. 2005 Sep;63(9):1647-53. Nihon Rinsho. 2005. PMID: 16164225 Review. Japanese.
Cited by
- Dihydroartemisinin Regulated the MMP-Mediated Cellular Microenvironment to Alleviate Rheumatoid Arthritis.
Guo Q, Wang Q, Chen J, Zhao M, Lu T, Guo Z, Wang C, Wong YK, He X, Chen L, Zhang W, Dai C, Shen S, Pang H, Xia F, Qiu C, Xie D, Wang J. Guo Q, et al. Research (Wash D C). 2024 Sep 10;7:0459. doi: 10.34133/research.0459. eCollection 2024. Research (Wash D C). 2024. PMID: 39257420 Free PMC article. - Analysis of common differential gene expression in synovial cells of osteoarthritis and rheumatoid arthritis.
Liao CS, He FZ, Li XY, Zhang Y, Han PF. Liao CS, et al. PLoS One. 2024 May 21;19(5):e0303506. doi: 10.1371/journal.pone.0303506. eCollection 2024. PLoS One. 2024. PMID: 38771826 Free PMC article. - Genetic Rare Variants Affecting Multiple Pathways in Japanese Patients with Palindromic Rheumatism.
Kawara T, Inoue K, Shiozawa S, Osawa K, Komai K. Kawara T, et al. Kobe J Med Sci. 2024 Apr 30;70(1):E26-E38. doi: 10.24546/0100489391. Kobe J Med Sci. 2024. PMID: 38719338 Free PMC article. - The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches.
Gupta N, Kanwar N, Arora A, Khatri K, Kanwal A. Gupta N, et al. Clin Rheumatol. 2024 May;43(5):1421-1433. doi: 10.1007/s10067-024-06932-5. Epub 2024 Mar 18. Clin Rheumatol. 2024. PMID: 38499817 Review. - Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.
Marasco E, Fabbriciani G, Rotunno L, Longhi M, De Luca P, de Girolamo L, Colombini A. Marasco E, et al. Front Immunol. 2023 Sep 19;14:1254139. doi: 10.3389/fimmu.2023.1254139. eCollection 2023. Front Immunol. 2023. PMID: 37809106 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical